Bayer (BAYN GY) executive says no change to 2026 guidance due to US pharmaceutical tariffs announced last week
Importance
Level 1
#GERMANY#EUROPE#BAYER AG#BAYN.GY#EQUITIES#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BAYN#EURO STOXX 50#DAX 40 INDEX